Delcath Systems, Inc.

NASDAQ (USD): Delcath Systems, Inc. (DCTH)

Last Price

9.82

Today's Change

+0.19 (1.97%)

Day's Change

9.59 - 9.98

Trading Volume

175,528

Overview

Market Cap

313 Million

Shares Outstanding

31 Million

Avg Volume

368,207

Avg Price (50 Days)

9.68

Avg Price (200 Days)

7.38

PE Ratio

-8.39

EPS

-1.17

Earnings Announcement

25-Mar-2025

Previous Close

9.63

Open

9.59

Day's Range

9.59 - 9.9798

Year Range

2.6 - 12.88

Trading Volume

175,574

Price Change Highlight

1 Day Change

1.97%

5 Day Change

6.74%

1 Month Change

-11.13%

3 Month Change

23.21%

6 Month Change

21.38%

Ytd Change

138.93%

1 Year Change

231.76%

3 Year Change

3.37%

5 Year Change

-68.83%

10 Year Change

-98.96%

Max Change

-98.96%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Medical Devices

Description:

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Discussions
Be the first to like this. Showing 1 of 1 comments

k6ii

Anyone here see this stock?

2016-09-21 10:41

Post a Comment